Shanghai LIFE Medical Science and Technology

Shanghai LIFE Medical Science and Technology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative cell and gene therapies (CGT). Founded in 2013, the company utilizes its proprietary induced pluripotent stem cell (iPSC) and mesenchymal stem cell (MSC) platforms to target a wide range of conditions, including respiratory, neurodegenerative, and metabolic diseases. Its lead program, a human umbilical cord-derived mesenchymal stem cell injection, is currently in Phase 1/2 clinical trials for interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Additionally, the company is advancing a robust pipeline of regenerative medicine candidates for indications such as diabetes, heart failure, and thalassemia, as well as CAR-T therapies for oncology. Shanghai LIFE operates GMP-compliant manufacturing facilities and maintains strategic collaborations with leading academic and medical institutions to drive the clinical translation of its cellular engineering technologies.